entertainment -WSS

entertainment

author：hotspot 2025-09-30 18:16:57 - browse：28957

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： eGenesis tests gene

WSS

Dewpoint Therapeutics lays off staff after losing partnerships

Chemotherapy drug shortage eases slightly but still widespread

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

My yearlong odyssey to get my son’s ADHD medication covered

FDA authorizes Novavax’s updated Covid

Francis Collins on trust in science and how Covid communications failed

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Bill would stop addiction treatment from triggering child abuse inquiry

DIEP, the 'gold standard' of breast reconstruction, is under threat

AI can decode, harness the power of the humane immune system

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Was Amgen transparent enough on FDA's concern on cancer drug?

Alkermes shareholders re

NIH director takes cautious approach to Biden drug pricing priority

Psychedelics group wrestles with new pharma identity

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

explore

Sana to lay off nearly a third of staff, de

Humana cuts profit projections as Medicare Advantage costs soar

AI can decode, harness the power of the humane immune system

Why age limits for politicians are a terrible idea

Prior authorization will have to move faster under new Biden rule

FDA authorizes Novavax’s updated Covid

knowledge

leisure time

focus

hotspot